We have studied the pharmacodynamics of the 1 R c/s-1'R cis isomer of atracurium (51W89) in 15 healthy subjects and in 17 patients with chronic renal failure using a bolus dose of 51W89 0.1 mg kg" 1 (2 x ED 95 ). Fifteen patients with normal renal function were investigated also using an approximately equipotent dose of atracurium (0.4mgkg~1). The compound surface action potential of the adductor pollicis muscle, in response to train-of-four stimulation of the ulnar nerve at the wrist, was recorded until recovery of the height of the first response of the train-of-four compared with baseline (T1 :T0) had reached at least 85% and the train-of-four ratio (T4:T1) at least 80%. In the healthy and renal failure patients who received 51W89, there were no significant differences in any of the onset or recovery variables except for the time to 90% depression of T1 :T0, which was longer in patients with renal failure (mean 3.7 min vs 2.4 min; P < 0.05). Of the healthy patients who were given either 51W89 or atracurium, there were no significant differences in the onset data, except for time to maximum block, which was longer in the 51W89 group (mean 7.7 min vs 6.2 min; / D <0.01). The mean times to 10%, 25%, 50% and 75% recovery of T1 :T0 and the time for T4:T1 > 70% were significantly longer in patients receiving 51W89. We conclude that 51W89 has an intermediate duration of action which was not significantly affected by the presence of chronic renal failure. In healthy patients, recovery from 51W89 may take slightly longer than that after atracurium. (Br.
The non-depolarizing neuromuscular blocking agent, atracurium besylate, is a benzylisoquinolinium compound with a symmetrical molecular structure containing four chiral centres [1] . There are 10 distinct isomers, of different potencies, which fall into three groups; cis-cis, cis-trans and transtrans, each comprising three, four and three variants, respectively [1, 2] . A preparation of one of these isomers, 1R cis-1'R-cis, designated 51W89, has been synthesized by the Wellcome Foundation Ltd and is now undergoing clinical trials. It constitutes about 15% of commercially produced atracurium [3] , is approximately three times more potent and has a similar intermediate duration of action [4, 5] . It produces less histamine release in animals than atracurium; for example, in cats, doses of 60 times the ED 95 did not significantly increase plasma histamine concentrations [3] . Dose-response studies conducted in humans suggest that the ED 95 is 0.05 mg kg" 1 [4, 5] . Atracurium is degraded in plasma by Hofmann degradation and ester hydrolysis; its clearance is believed to be independent of renal function [6] . The pharmacodynamics and pharmacokinetics of atracurium are not significantly altered by chronic renal failure [7, 8] and thus it has become the neuromuscular blocking agent of choice for patients with such diseases. The main purpose of this study was to investigate the pharmacodynamics of 51W89 in healthy patients and those with end-stage renal failure. In addition, we studied a group of healthy patients, using an approximately equipotent dose of atracurium, in order to compare the pharmacodynamic profiles of the isomer with atracurium in healthy patients with normal renal function.
Patients and methods
The study of 51W89 was approved by the Committee of Safety of Medicines and the hospital Ethics Committee. All patients gave written informed consent. Two groups of patients were given 51W89 0.1 mg kg" 1 ; one group of 17 patients with chronic renal failure and a control group of 15 patients, ASA I or II, with normal renal function. An additional group of 15 healthy patients, ASA I or II, were given atracurium 0.4mgkg-' (the dose of 51W89 was expressed as mg of the parent bis-cation and the dose of atracurium as mg of atracurium salt). The renal failure patients were undergoing surgery for fashioning of an arteriovenous fistula (n = 9), insertion of a CAPD catheter (« = 5), renal transplant nephrectomy (w = 2) or femoropopliteal graft (n = 1 On induction of anaesthesia, electromyographic (EMG) neuromuscular monitoring was commenced using a Medelec MS6 electromyograph. Supramaximal, train-of-four (TOF) stimuli were applied to the ulnar nerve at the wrist every 12.5 s and the evoked surface compound action potential of the adductor pollicis muscle displayed on an oscilloscope and recorded on light-sensitive paper. The arm was wrapped in cotton wool padding to maintain skin temperature. The EMG trace was stabilized and a 3-5-min recording made to act as the control during subsequent analysis.
When baseline recordings had been obtained, a bolus dose of 51W89 O.lmgkg" 1 (2 x ED 95 ) or atracurium 0.4 mg kg" 1 (2 x ED 95 ) was given over 10 s into a fast flowing peripheral i.v. infusion. The onset of neuromuscular block and subsequent spontaneous recovery were recorded continuously until the height of the first response of the TOF compared with control (Tl :T0) had recovered to at least 85 % and the TOF ratio, T4:T1, had achieved at least 80%. No increments of neuromuscular blocking agent or anticholinesterase were given.
Tracheal intubation was attempted 2 min after administration of the drug and again at 1-min intervals if the initial attempt was unsuccessful. Intubating conditions were graded as excellent (no movement), good (slight cough, jaw and cords well relaxed), poor (cough or movement, cords moderately adducted) or impossible [9] . Ventilation was controlled and end-tidal Pco 2 maintained at 4.3-5.6 kPa. At the end of surgery and when the height of T4:T1 was greater than 80%, anaesthesia was discontinued and spontaneous ventilation established. After pharyngeal suction, the trachea was extubated when appropriate and patients transferred to the recovery room, where they were observed for at least 1 h. All patients were assessed in the recovery area for clinical evidence of residual neuromuscular block before return to the ward.
The following day patients were examined and asked specifically about muscle aches, weakness and recall of perioperative events. All patients who had been given 51W89 had postoperative measurements of haemoglobin, full blood count, plasma urea and electrolyte concentrations and liver function tests.
The EMG trace for each patient was analysed to determine the onset times to 90%, 95% and maximum depression of Tl:T0. Maximum depression of Tl :T0 was also recorded. The times for Tl:T0 to reach 5%, 10%, 25%, 50%, 75% and 90% were noted. The recovery index (time for Tl:T0 to recover from 25% to 75%) was also calculated for each patient, as was the time for T4:T1 to achieve 70%.
Pharmacodynamic variables for the renal failure and healthy patients receiving 51W89 were compared using the Mann-Whitney U test, as were the dynamic variables of the patients receiving atracurium compared with the healthy patients receiving 51W89. The variance in recovery times for the renal and healthy patients given 51W89 was compared using the F test.
Results
Mean age, weight, height and male to female ratios were similar for the three groups of patients. The degree of renal impairment in the patients with renal failure who received 51W89 was reflected in a mean preoperative creatinine concentration of 823 umol litre" 1 (table 1). All patients with renal failure were receiving regular dialysis except one, who was undergoing a primary vascular access procedure.
Comparing the healthy and renal failure patients who received 51W89, the mean time to 90% depression was more than 1 min longer in the renal failure patients (3.7 min vs 2.4 min; P < 0.05). There was no significant difference in the mean time to 95 % block, time to maximum block or in the maximum block achieved between the groups (table 2) .
When the two healthy groups were compared, there were no differences in the mean times to 90 % and 95 % depression or in the maximum depression obtained. The mean time to maximum depression was, however, significantly longer in the patients receiving 51W89 (7.7 min vs 6.2 min; P < 0.01).
After 51W89 the mean times to 75% and 90% recovery of T1: TO, the recovery index and the time for T4:T1 > 70% were longer in the renal failure group, but these differences were not statistically significant using the Mann-Whitney U test (table 3) . There was more marked variability in the recovery variables in the renal failure patients; using the F test, the SD was significantly greater for 10%, 25 %, 50% and 75% recovery of Tl:T0 and T4:T1 > 70 % than in healthy patients. When the two healthy groups of patients were compared, the mean times to 10%, 25%, 50% and 75% recovery of Tl:T0 and the mean time for T4: T1 to reach 70 % were significantly longer in the patients receiving 51W89 than in those receiving atracurium. The recovery index was also longer in the isomer group, although this difference was not statistically significant.
There was no local or systemic evidence of histamine release in any patient receiving atracurium or 51W89.
The times to tracheal intubation and intubating conditions achieved are shown in table 4. When assessed the following day, no patient complained of muscle pains, weakness, dreaming or awareness in the perioperative period.
Discussion
Until the introduction of atracurium in 1982, all the available non-depolarizing neuromuscular blocking agents depended significantly on renal excretion for elimination. Tubocurarine [10] , gallamine [11] , alcuronium [12] , pancuronium [13] and metocurine [14] are cleared by the kidney and therefore may have a prolonged action in patients with renal failure. In contrast, the plasma clearance of atracurium, which is broken down by Hofmann degradation and ester hydrolysis, is independent of hepatic and renal function [6] . It has been shown that the pharmacodynamics and pharmacokinetics of atracurium are not significantly different in patients with renal failure compared with healthy controls [7, 8] . Concern has been expressed that laudanosine, one of the metabolites of Hofmann degradation, is epileptogenic in animals (although it does not have neuromuscular blocking activity) [15] . Laudanosine is excreted in part by the kidney and -may therefore cumulate in renal failure [16] .
Vecuronium is excreted in part by the kidney (30%) and undergoes deacetylation in the liver to hydroxy metabolites [17] . Early studies suggested that its duration of action was not prolonged by renal failure [18] . However, it has become apparent that vecuronium may cumulate if given in repeated bolus doses or by constant infusion to such patients: several cases of prolonged neuromuscular block after vecuronium have been reported in such circumstances [19, 20] . The more recently developed neuromuscular blocking agent mivacurium, may have a slightly prolonged action in renal failure; this is thought to be associated with reduced plasma cholinesterase activity [21] . There is also evidence that the action of rocuronium and doxacurium may be prolonged in renal disease [22, 23] . In our opinion, atracurium remains the neuromuscular blocking agent of choice for the majority of patients with this condition.
51W89 is a preparation of one of the 10 isomers which constitute atracurium. It is important to ascertain if it behaves similar to the isomeric mixture in patients with renal failure. This study has shown that, following a bolus dose of 51W89, the profiles for onset and recovery from neuromuscular block were very similar in patients with end-stage renal failure to those patients with normal renal function. The only significant difference was in the mean time to 90 % depression of Tl: TO, which was more than 1 min longer in the renal failure patients given 51W89. A delayed onset of action in patients with renal failure compared with healthy controls has also been described for atracurium, vecuronium and tubocurarine [24] and is thought to result from a lower cardiac output in the sicker renal group (especially after receiving thiopentone). No such effect was found after rocuronium had been given in renal failure patients [22] . It must be stressed that the anaesthetic technique used here varied from normal clinical practice; the neuromuscular blocking agent was given several minutes after induction of anaesthesia. Thus the onset of action of 51W89 also needs to be studied in more typical clinical circumstances.
The rinding of a greater variability in mean recovery times in renal failure patients is not new [22] ; it is unexplained, but not surprising. Many different pathological conditions result in end-stage renal failure; within each disease state there is also major physiological variability.
When the neuromuscular blocking profiles of 51W89 and atracurium in patients with normal renal function were compared, there was no difference in the mean times to 90% and 95% depression of Tl:T0 with this sample size, but the time to maximum block was longer in the isomer group. We have calculated, post hoc, that to have had a 90% chance of finding a 50 % increase in the onset times with 51W89 compared with atracurium, we would need to have studied 26 patients in each group; we studied only 15-17 patients. This difference in onset may be explained partly by the absence of the action of the shorter acting isomers present in atracurium. It could have been expected; there is evidence that onset of neuromuscular block may take longer with a more potent non-depolarizing agent than with an equivalent dose of a less potent one [25] .
The mean recovery times for patients receiving the isomer were in general longer than those receiving atracurium. We used an ED 95 for atracurium of 0.2 mg kg" 1 [26] , although this value is now thought to be nearer 0.22 mg kg" 1 [27] if neuroleptanaesthesia is used. If we had used a slightly higher dose, however, it could be predicted that the onset of action of atracurium would have been even more rapid than 51W89, but that the differences in recovery times may have been slightly less than reported here.
Plasma laudanosine concentrations after 51W89 have not yet been reported. As 51W89 is more potent than atracurium, a smaller mass of drug is given. If the two agents undergo the same degree of Hofmann degradation, it may be expected that less laudanosine would be produced. This would be reassuring to clinicians concerned about the adverse effects of this metabolite, especially in the presence of renal dysfunction.
